타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 3개 · 임상 갱신 필요 3개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |||
|---|---|---|---|
Overview Program | Tremfya (guselkumab) | Skyrizi (risankizumab-rzaa) | Stelara (ustekinumab) |
Overview Company | Johnson & Johnson | AbbVie | Johnson & Johnson |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | IL-23 p19 | IL-23 p19 | IL-12 / IL-23 (p40) |
Overview Indication | Plaque psoriasis, psoriatic arthritis, ulcerative colitis, Crohn's disease | Plaque psoriasis, PsA, Crohn's disease, ulcerative colitis | Psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis |
Overview Phase | APPROVED | APPROVED | APPROVED |
Overview Status | APPROVED | APPROVED | APPROVED |
Overview Content status | Curated Core | Curated Core | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Established |
Overview Approval status | FDA approved | FDA approved | FDA approved |
Positioning Key differentiator | Leaving IL-12 intact preserves Th1 antimicrobial immunity while shutting down the Th17 axis, which is why durability is high and infection signals are low. | Novel therapeutic avenues, including TYK2 and HDAC inhibitors, as well as nanotechnology-based delivery systems, show encoura | Novel therapeutic avenues, including TYK2 and HDAC inhibitors, as well as nanotechnology-based delivery systems, show encoura |
Positioning Known limitation | Anti-drug antibodies are rare; non-IL-23-driven fibrostenotic disease does not respond. | IL-17 independent disease and immunogenicity. | IL-23 axis escape, anti-drug antibodies, and non-IL-12/23 inflammation. |
Positioning Development positioning | 1L–2L biologic across dermatology, rheumatology, and gastroenterology | — | — |
MoA Mechanism | Neutralizes IL-23 by binding p19, blocking IL-23R signaling and downstream Th17/Th22 differentiation, IL-17 production, and tissue inflammation in skin, joints, and gut mucosa. | Risankizumab selectively binds IL-23 p19 subunit, blocking IL-23 interaction with IL-23R and downstream Th17 pathway (IL-17A/F, IL-22). | Ustekinumab binds the p40 subunit shared by IL-12 and IL-23, preventing their interaction with IL-12Rβ1 receptor and downstream Th1/Th17 differentiation and cytokine production. |
MoA Biomarker | PASI/IGA in psoriasis, ACR20 in PsA, endoscopic improvement and fecal calprotectin in IBD. | PASI, sPGA, IBD endoscopic scores. | biomarkers but require external validation in independent cohorts |
Toxicology Species | Pig | Cynomolgus monkey | Cynomolgus monkey, Mouse |
Toxicology Major finding | Upper respiratory infection, headache, and injection-site reactions dominate. Serious infection and malignancy signals have stayed low across long-term psoriasis follow-up. | Upper respiratory infections, headache, fatigue; low TB reactivation vs TNF class. | Infections, reversible posterior leukoencephalopathy syndrome (rare), hypersensitivity. |
Toxicology CRS | N/A | N/A | N/A |
Clinical Safety signal | Upper respiratory infection, headache, and injection-site reactions dominate. Serious infection and malignancy signals have stayed low across long-term psoriasis follow-up. | Upper respiratory infections, headache, fatigue; low TB reactivation vs TNF class. | Infections, reversible posterior leukoencephalopathy syndrome (rare), hypersensitivity. |
Clinical Program phase | APPROVED | APPROVED | APPROVED |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 3개 · 임상 갱신 필요 3개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |||
|---|---|---|---|
Overview Program | Tremfya (guselkumab) | Skyrizi (risankizumab-rzaa) | Stelara (ustekinumab) |
Overview Company | Johnson & Johnson | AbbVie | Johnson & Johnson |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | IL-23 p19 | IL-23 p19 | IL-12 / IL-23 (p40) |
Overview Indication | Plaque psoriasis, psoriatic arthritis, ulcerative colitis, Crohn's disease | Plaque psoriasis, PsA, Crohn's disease, ulcerative colitis | Psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis |
Overview Phase | APPROVED | APPROVED | APPROVED |
Overview Status | APPROVED | APPROVED | APPROVED |
Overview Content status | Curated Core | Curated Core | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Established |
Overview Approval status | FDA approved | FDA approved | FDA approved |
Positioning Key differentiator | Leaving IL-12 intact preserves Th1 antimicrobial immunity while shutting down the Th17 axis, which is why durability is high and infection signals are low. | Novel therapeutic avenues, including TYK2 and HDAC inhibitors, as well as nanotechnology-based delivery systems, show encoura | Novel therapeutic avenues, including TYK2 and HDAC inhibitors, as well as nanotechnology-based delivery systems, show encoura |
Positioning Known limitation | Anti-drug antibodies are rare; non-IL-23-driven fibrostenotic disease does not respond. | IL-17 independent disease and immunogenicity. | IL-23 axis escape, anti-drug antibodies, and non-IL-12/23 inflammation. |
Positioning Development positioning | 1L–2L biologic across dermatology, rheumatology, and gastroenterology | — | — |
MoA Mechanism | Neutralizes IL-23 by binding p19, blocking IL-23R signaling and downstream Th17/Th22 differentiation, IL-17 production, and tissue inflammation in skin, joints, and gut mucosa. | Risankizumab selectively binds IL-23 p19 subunit, blocking IL-23 interaction with IL-23R and downstream Th17 pathway (IL-17A/F, IL-22). | Ustekinumab binds the p40 subunit shared by IL-12 and IL-23, preventing their interaction with IL-12Rβ1 receptor and downstream Th1/Th17 differentiation and cytokine production. |
MoA Biomarker | PASI/IGA in psoriasis, ACR20 in PsA, endoscopic improvement and fecal calprotectin in IBD. | PASI, sPGA, IBD endoscopic scores. | biomarkers but require external validation in independent cohorts |
Toxicology Species | Pig | Cynomolgus monkey | Cynomolgus monkey, Mouse |
Toxicology Major finding | Upper respiratory infection, headache, and injection-site reactions dominate. Serious infection and malignancy signals have stayed low across long-term psoriasis follow-up. | Upper respiratory infections, headache, fatigue; low TB reactivation vs TNF class. | Infections, reversible posterior leukoencephalopathy syndrome (rare), hypersensitivity. |
Toxicology CRS | N/A | N/A | N/A |
Clinical Safety signal | Upper respiratory infection, headache, and injection-site reactions dominate. Serious infection and malignancy signals have stayed low across long-term psoriasis follow-up. | Upper respiratory infections, headache, fatigue; low TB reactivation vs TNF class. | Infections, reversible posterior leukoencephalopathy syndrome (rare), hypersensitivity. |
Clinical Program phase | APPROVED | APPROVED | APPROVED |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts |
추천 비교
추천 비교